据世界卫生组织报道,全球约20亿人曾感染过乙肝病毒,乙型肝炎仍然严重威胁人类健康,其中很大一部分都会发展成为慢性肝炎、肝硬化甚至肝癌[1]。目前常见的乙肝治疗药物主要以核苷(酸)类似物及干扰素为主,但由于存在疗程长、副作用严重及停药后反弹等因素,目前的治疗效果仍不理想[2]。近年来的研究表明,机体特异性免疫功能低下,尤其 According to the World Health Organization, about 2 billion people worldwide have been infected with hepatitis B virus. Hepatitis B remains a serious threat to human health. A large proportion of them will develop chronic hepatitis, cirrhosis and even liver cancer [1]. At present, common hepatitis B therapeutic drugs are mainly nucleoside (acid) analogues and interferons, but due to factors such as long course of treatment, serious side effects and rebound after drug withdrawal, the current treatment effect is still not satisfactory [2]. In recent years, studies have shown that the body-specific immune function is low, especially